Equity Profile

ZLAB

Zai Lab Limited

Health CareBiotechnology$2.9B

Nov29Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close9:00 AM EST

Company Snapshot

Zai Lab Limited is a biotechnology company focused on developing innovative medicines to address unmet medical needs in China and globally. Operating in the health care sector, Zai Lab is involved in the research and development of therapies for cancer and autoimmune diseases, making it a significant player in the biotech industry.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will show how well Zai Lab is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ZLAB Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+0.83%

Avg Stock Reaction

-3.30%

Last Quarter Recap

In the last quarter, Zai Lab reported an EPS of -$0.46, which was better than the expected -$0.58, resulting in a positive surprise. However, the stock dropped 5.93% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of Zai Lab's earnings report, as there are no analyst estimates available, making it difficult to gauge market expectations. The company has shown mixed performance in the past, with a 50% EPS beat rate.

Bull Case

If Zai Lab can demonstrate significant progress in its drug development pipeline and report better-than-expected EPS, it could restore investor confidence and drive the stock price higher.

Bear Case

Conversely, if the company fails to show improvement in its financials or provides weak guidance, it may lead to further declines in stock price, especially given its recent history of disappointing results.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

This figure will be crucial in determining whether Zai Lab can maintain investor confidence after its mixed performance in previous quarters.

What updates can management provide on the drug pipeline and revenue growth?

Insights into the drug pipeline and revenue potential will be key to understanding the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Zai Lab's potential for a turnaround based on its recent EPS surprise, which could indicate improved operational efficiency.

Supporting Evidence

Zai Lab has a 50% EPS beat rate, suggesting a reasonable chance of exceeding expectations.

The significant implied move in options indicates that traders are anticipating volatility, which could favor a positive surprise.

Key Risk

If Zai Lab reports an EPS better than -$0.40, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing Zai Lab's ability to execute on its growth strategy and manage investor expectations.

Bull Confirmed If

An EPS of -$0.40 or better, along with positive commentary on the drug pipeline, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.50, coupled with negative guidance on revenue growth, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±32.08%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect substantial volatility around the earnings announcement.

Options are pricing ±32.1% while ZLAB has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.2%

Calls (400)P/C Ratio: 52.33Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zai Lab beats expectations, history suggests the stock could see an average one-day move of around -5.50%, indicating a potential sell-off despite the positive news.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing investor uncertainty.

Miss

If Zai Lab misses expectations, history suggests a potential decline of about -1.10%, which could further erode investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug trials and expected timelines for results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Zai Lab's products and competitive positioning.
4Any guidance on revenue expectations for the upcoming quarters.
5Details on partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

The Buckle, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will show how well Zai Lab is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ZLAB Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+0.83%

Avg Stock Reaction

-3.30%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Zai Lab can demonstrate significant progress in its drug development pipeline and report better-than-expected EPS, it could restore investor confidence and drive the stock price higher.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

This figure will be crucial in determining whether Zai Lab can maintain investor confidence after its mixed performance in previous quarters.

What updates can management provide on the drug pipeline and revenue growth?

Insights into the drug pipeline and revenue potential will be key to understanding the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Zai Lab's potential for a turnaround based on its recent EPS surprise, which could indicate improved operational efficiency.

Supporting Evidence

Zai Lab has a 50% EPS beat rate, suggesting a reasonable chance of exceeding expectations.

The significant implied move in options indicates that traders are anticipating volatility, which could favor a positive surprise.

Key Risk

If Zai Lab reports an EPS better than -$0.40, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in assessing Zai Lab's ability to execute on its growth strategy and manage investor expectations.

Bull Confirmed If

An EPS of -$0.40 or better, along with positive commentary on the drug pipeline, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.50, coupled with negative guidance on revenue growth, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±32.08%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect substantial volatility around the earnings announcement.

Options are pricing ±32.1% while ZLAB has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.2%

Calls (400)P/C Ratio: 52.33Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zai Lab beats expectations, history suggests the stock could see an average one-day move of around -5.50%, indicating a potential sell-off despite the positive news.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing investor uncertainty.

Miss

If Zai Lab misses expectations, history suggests a potential decline of about -1.10%, which could further erode investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug trials and expected timelines for results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Zai Lab's products and competitive positioning.
4Any guidance on revenue expectations for the upcoming quarters.
5Details on partnerships or collaborations that could enhance growth prospects.